Radius Health, Inc. 4
4 · Radius Health, Inc. · Filed Feb 19, 2014
Insider Transaction Report
Form 4
Muenchbach Martin
Director
Transactions
- Award
Series B-2 Convertible Preferred Stock
2014-02-14$61.42/sh+12,211$750,000→ 12,211 total(indirect: By Fund)From: 2014-02-14→ Common Stock (122,110 underlying) - Award
Common Stock Warrant
2014-02-14+30,528→ 111,936 total(indirect: By Fund)Exercise: $6.14From: 2014-02-14Exp: 2019-02-14→ Common Stock (30,528 underlying)
Footnotes (3)
- [F1]Each share of the Series B-2 Convertible Preferred Stock has no expiration date and is convertible at any time, in whole or in part, at the election of the holder at a conversion rate of 10 shares of Common Stock for every 1 share of Series B-2 Convertible Preferred Stock.
- [F2]Payment of an aggregate purchase price equal to the product of (i) $61.42 multiplied by (ii) the total number of reported shares of Series B-2 Convertible Preferred Stock, entitled the purchaser to receive the reported shares of Series B-2 Convertible Preferred Stock as well as the reported warrant exercisable for shares of Common Stock.
- [F3]The reported securities are owned directly by BB Biotech Ventures II L.P. ("BBBV LP"). BB Biotech Ventures GP (Guernsey) Limited ("BBBV Limited") is the General Partner of BBBV LP. The reporting person is a Senior Investment Advisor Private Equity at Bellevue Asset Management AG ("BAM AG") and advises Asset Management BAB N.V. ("AMB NV") who, pursuant to a services agreement with BAM AG, advises the directors of BBBV Limited. The reporting person shares voting and investment power over the BBBV LP shares. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.